Rosen Law Firm reminded investors about a pending class action against ARS Pharmaceuticals, Inc. involving alleged misstatements about the expected timing of expanded CVS Caremark insurance coverage for neffy, the company’s epinephrine nasal spray. The alleged Class Period runs from March 9, 2026, through June 24, 2026, inclusive. The lawsuit claims ARS expressed confidence that expanded coverage would begin July 1, 2026, and cover the summer and back-to-school allergy seasons while concealing adverse information about the timeline. Investors have until October 5, 2026, to seek appointment as lead plaintiff. Rosen said eligible investors may participate through a contingency-fee arrangement without upfront fees or costs. No class has been certified, and investors may also remain absent class members. Bragar Eagel & Squire previously announced the filing and said eligible investors could contact its attorneys at no cost or obligation.